http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
랫드에서 새로운 Anthracycline계 항암제 Hyrubicin ID6105에 대한 4주 반복투여 독성연구
장호송,서동석,인창훈,황재식,이수해,정미숙,신지순,이홍섭,유정수,김태영,김윤배,강종구 한국독성학회 2002 Toxicological Research Vol.18 No.4
Repeated-dose toxicity of hyrubicin ID6105, a novel anthracycline anticancer agent, was investigated in Sprague-Dawley rats. ID6105 was injected intravenously to rats at dose levels of 0.04, 0.2 or 1.0 mg/kg/day for 4 weeks. As a result, there were no dose-related mortality and specific clinical signs of all animals treated with the drug. However, body weight gain of both male and female rats treated with a high dose (1.0mg/kg/day) of ID6105 significantly decreased compared to control. Interestingly, the numbers of RBC and platelets, and concentration of hemoglobin remarkably increased, while protein synthesis was suppressed, which may be related to the atrophy of spleen, thymus and liver. Moreover, there were severe lymphocytic depletion in spleen and thymus as well as decrease in the number of hematopoletic cells in bone marrow. Also, degeneration of cardiac muscles and testicular germinal epithelia were observed. Taken together, it is suggested that long-term administration of ID6105 at high doses over 0.2mg/kg/day might cause hematopoietic and male reproductive system injuries, in addition to hepatic dysfunction.